MARKETS / NASDAQ / PULM
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Pulmatrix, Inc. PULM

13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-1.41
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-80.9%
Net margin · FY25
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
Revenue, FY2025 · full 13-year series below
Revenue Net income
0.0040.0080.0120.016-0.020132016201920222025
0.0040.0080.0120.016-0.02016201920222025

Per share
USD -1.41
Diluted EPS, FY2025
EPS
0.40.81.2-1.4120132016201920222025
0.40.81.2-1.412016201920222025

The company pays no cash dividend.

Profitability
-80.9%
Return on equity, FY2025
ROE
0.250.50.751-80.9%20132016201920222025
0.250.50.751-80.9%2016201920222025
Operating margin
Net margin
Return on assets-73.3%

Each USD of equity lost 81 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
−0.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+14.7%
−0.3%
+36.3%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.000.0020132016201920222025
0.010.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.1M
total assets, end of FY2025
Total assetsUSD 4.1M
EquityUSD 3.8M
CashUSD 4.1M
Current ratio12.55×

Equity funds 92% of total assets.

History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
−0.0
−0.0
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
·
·
·
·
·
·
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.41
−2.62
−3.87
−5.46
−8.63
−13.43
−1.23
−4.98
−9.32
−1.88
−3.23
−34.52
−1.53
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−80.9
−71.0
−57.5
−48.0
−57.2
−113.1
−180.2
−187.1
−191.1
−134.6
·
·
−42.5
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.01
0.01
0.00
0.00

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed